Tag

Mark Saldanha

2 articles

Marksans Pharma FY26 Revenue Hits Record ₹3,033 Cr

Marksans Pharma reported its highest-ever annual revenue of ₹3,033 crore, EBITDA of ₹601 crore, and PAT of ₹420 crore for FY26. Q4FY26 revenue grew 23.1% YoY to ₹891 crore, driven by strong performanc

Marksans Pharma Q4FY26 PAT Up 64% YoY

Marksans Pharma reported Q4FY26 PAT of ₹149 crore, up 64.3% YoY, with total income at ₹891 crore. FY26 consolidated revenue reached ₹3,034 crore, a record high, with EBITDA at ₹601 crore and PAT of ₹4